Clinical features and risk factors for infecfions in multiple myeloma during chemotherapy

doi:10.12092/j.issn.1009-2501.2018.01.018

Abstract

Abstract:

AIM: To observe the clinical characteristics of infections in multiple myeloma (MM) patients during chemotherapy in hospital, and to identify the risk factors for infection and provide the basis for prevention and control of nosocomial infections. METHODS: A retrospective study of patients with MM who underwent chemotherapy between Jan 2012 and Mar 2016 in the First Affiliated Hospital of Jiaxing University was conducted. Clinical features and risk factors for infections were analyzed. RESULTS: One hundred and fifty three patients with MM received a total of 415 courses of chemotherapies. During which 150 (36.14%) infections episodes occurred. The common infections sites were respiratory tract infection (49.25%), gastrointestinal tract infection (16.42%), urinary tract infection (13.43%) and oral infection (7.46%).Seventy-four strains of pathogenic bacteria were detected. Gram-negative bacteria were observed in 71.62% of documented pathogens, and Gram-positive bacteria were responsible for 17.57% of infections. Multivariate unconditioned logistic analysis of factors identified consistent independent risk factors for complication of diabetes mellitus（95%CI:6.572-80.650, OR=22.359, P<0.001）, hospitalization time longer than 20 days（95%CI:1.785-29.169, OR=17.328, P<0.001）, and high ISS stage（95%CI: 4.974-35.247, OR=12.894, P<0.001). CONCLUSION: Patients with MM tended to be infected with various species of pathogens after the chemotherapy; MM patients with complication of diabetes mellitus, hospitalization time longer than 20 days, and high ISS stage faced an increased risk of infections by multivariate analysis. It is necessary for the hospital to strengthen the risk assessment for the patients and take effective prevention and control measures for the patients complicated with diabetes, hospitalization interval longer than 20 days, or high ISS stage.

Key words: multiple myeloma, infection, risk factors, pathogen

CLC Number:

R733. 3

WU Haibing, ZHANG Gang, HAN Bin, GUO Xiaojun, JI Zhaoning. Clinical features and risk factors for infecfions in multiple myeloma during chemotherapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 93-98.

References

［1］Turesson I, Velez R, Kristinsson SY, et al．Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic［J］. Mayo Clin Proc, 2010, 85(3): 225-230.
［2］Li J,Li Y,Huang BH, et al. Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy［J］ .Cell Biochem Biophys, 2015,71:457-464.
［3］Teh BW, Harrison SJ, Pellegrini M, et al. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection［J］. Blood Rev, 2014, 28(2):75-86.
［4］中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员,等．中国多发性骨髓瘤诊治指南（2015年修订）［J］．中华内科杂志, 2015,54(12): 1066-1070.
［5］中华人民共和国卫生部．医院感染诊断标准(试行)［J］．中华医学杂志, 2001, 81(5): 314-320．
［6］中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则［J］. 中华内科杂志, 2013, 52(8): 704-709．
［7］中华医学会血液学分会, 中国医师协会血液科医师分会.中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南［J］.中华血液学杂志, 2016, 37（5）: 353-359.
［8］叶应妩, 王毓三, 申子瑜.全国临床检验操作规程［M］.南京: 东南大学出版社，2006: 736,753．
［9］陈文婷, 姚红霞, 吴巨峰, 等.多发性骨髓瘤患者化疗后感染的研究［J］.中华医院感染学杂志, 2014, 24（23）：5849-5851.
［10］Toni V, Vedrana G, Jelena I, et al.Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors［J］.Turk J Hematol, 2015, 32:234-242.
［11］陈莉莉，唐小万，江文华，等.多发性骨髓瘤患者化疗后医院感染病原菌分布及危险因素分析［J］.中华医院感染学杂志, 2014, 24（21）：5365-5367.
［12］石岳坚，俞康，郑翠苹，等．多发性骨髓瘤患者医院感染原因分析与控制［J］.中华医院感染学杂志，2014，24（11）：2743-2747.
［13］吴隼，马栋，杨满，等.多发性骨髓瘤患者医院感染的临床特点分析［J］.中华医院感染学杂志，2013，23（17）：4181-4183.
［14］闫晨华,徐婷,郑晓云,等.中国血液病患者中性粒细胞缺乏伴发热的多中心、前瞻性流行病学研究［J］.中华血液学杂志,2016, 37（3）: 177-182.
［15］胡付品, 朱德妹, 汪复, 等. 2014 年CHINET中国细菌耐药性监测［J］.中国感染与化疗杂志, 2015, 15（5）: 401-410.
［16］王宙政，韩艳霞，胡蓓莉，等.202例多发性骨髓瘤医院感染临床分析［J］.中华医院感染学杂志，2013，23（2）：347-349.
［17］Bryant AL，Deal AM，Walton A，et al．Use of ED and hospital services for patients with acute leukemia after induction therapy：one year follow-up［J］．Leuk Res, 2015, 39(4):406-410．
［18］李淑美，王用斌，赵欣，等．急性白血病患者医院感染影响因素Logistic回归分析［J］．中国病原生物学杂志，2010，5（11）：858-861.
［19］Garcia JB，Lei X，Wierda W，et al．Pneumonia during remission induction chemotherapy in patients with acute leukemia［J］．Ann Am Thorac Soc, 2013, 10(5):432-440．
［20］ Pereira CA，Marra AR，Camargo LF, et al．Nosocomial bloodstream infections in Brazilian pediatric patients：microbiology, epidemiology and clinical features［J］．PLoS One, 2013, 8(7): e68144．
［21］Rhee Y，Heung M，Chen B，et al．Central line-associated bloodstream infections in non-ICU inpatient wards：a 2-year analysis［J］．Infect Control Hosp Epidemiol, 2015, 36(4): 424-430．
［22］Kugler E, Levi A, Goldberg E, et al．The association of central venous catheter placement timing with infection rates in patients with acute leukemia［J］．Leuk Res, 2015, 39(3): 311-313．
［23］Merrill KC, Sumner S, Linford L, et al．Impact of universal disinfectant cap implementation on central line--associated bloodstream infections［J］. Am J Infect Control, 2014, 42(12): 1274-1277.

[1]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[2]	ZHANG Mingkang, MA Yanrong, JIN Yongwen, ZHOU Yan, CUI Ruirui, WU Xin'an. Advances in clinical research on drug-induced acute interstitial nephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 419-428.
[3]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[4]	HUANG Huizhen, HAN Lei, LIN Xiaodong, CHEN Lei. Research progress on signal pathways related to the pathogenesis of pancreatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 109-113.
[5]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[6]	DUAN Yuanyuan, LI Zijian. Ciltacabtagene autoleucel—a novel BCMA-directed CAR T-cell therapy in patients with relapsed or refractory multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1145-1154.
[7]	HU Linlin, XU Silu, LI Weilan, HE Jie, ZHANG Jinglu, SHAO Hua. Effects of extracorporeal membrane oxygenation on pharmacokinetics and pharmacodynamics of daptomycin in critically ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 39-46.
[8]	FU Xiangjun, HUANG Li, GUO Li, LIN Liangmo. Application of AUC/MIC as the therapeutic drug monitoring target of vancomycin in patients with severe infections of multi drug resistant gram positive bacteria [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 775-781.
[9]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[10]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[11]	JIN Jing, CHENG Hong. Research progress of mitochondrial energy metabolism involved in the pathogenesis of depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1193-1199.
[12]	ZHOU Yiwen, PING Yi. Research progress on the mechanism and treatment of pelvic organ prolapse [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 595-600.
[13]	YANG Yanlang, LI Yan, WANG Lin. Distribution and drug resistance of bacterial pathogens in the infecting inpatients of department of nephrology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 203-208.
[14]	CHANG Xiangxiang, WEI Zhongling, ZHENG Xingyuan, LI Huimin, HUANG Laiquan. Progress in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 107-116.
[15]	SUN Kaikai, HUANG Chunhong, WANG Yunyun, WU Wei, CHEN Zhi. Detection of T lymphocyte surface costimulatory molecules and T lymphocyte subsets in peripheral blood of HBV infected patients and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 241-247.